Tolazamide is an oral blood glucose lowering drug used for people with Type 2 diabetes. It is part of the sulfonylurea family (ATC A10BB). Synthesis
para-Toluenesulfonamide is converted to its carbamate with ethyl chloroformate in the presence of a base. Heating that intermediate with 1-amino-azepane leads to the displacement of the ethoxy group and the formation of tolazemide:Azepane proper would lead to [13078-23-4]. References
External links
"Tolazamide". Medline Plus. U.S. National Library of Medicine.
At week 12, participants who received placebo were reassigned to upadacitinib daily.The benefit of upadacitinib was measured by comparing the proportion of participants treated with upadacitinib who achieved an American College of Rheumatology 20 (ACR20) response at week 12 or week 14 to the proportion of participants treated with MTX or placebo who achieved an ACR20 response. ACR20 is a 20% improvement in signs and symptoms of RA.Upadacitinib was approved for medical use in the European Union in December 2019. Research
Upadacitinib has also demonstrated success in treating moderate to severe atopic dermatitis and has been found to have superior efficacy compared with placebo and dupilumab. References
External links
"Upadacitinib". Drug Information Portal. U.S. National Library of Medicine.